Health Economics›Small cell lung cancer›Extensive stage induction

Extensive stage induction

Small cell lung cancer · 39 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 7 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Carboplatin and Paclitaxel (CP) and Ipilimumab Variant #01	—	R 788 798	21d	—	~13.4 mo	~6	~R 3 160 481 PFS proxy · indirect	1
Carboplatin and Etoposide (CE) and Durvalumab Variant #01	—	R 265 970	28d	—	12.9 mo	4	R 800 480 PFS proxy	2
Cisplatin and Etoposide (EP) and Durvalumab Variant #01	—	R 265 074	28d	—	12.9 mo	4	R 796 894 PFS proxy	3
Carboplatin and Etoposide (CE) and Pembrolizumab Variant #01	—	R 84 556	21d	—	—	35	R 2 879 828 PFS proxy	1
Cisplatin and Etoposide (EP) and Pembrolizumab Variant #01	—	R 83 659	21d	—	—	35	R 2 876 242 PFS proxy	1
Carboplatin and Etoposide (CE) and Atezolizumab Variant #01	—	R 33 823	21d	—	12.3 mo	5	R 166 548 PFS proxy	1
Carboplatin and Etoposide (CE) and Bevacizumab Variant #01	—	R 32 555	21d	5.5 mo	—	4	R 130 220 PFS proxy	1
Cisplatin and Etoposide (EP) and Bevacizumab Variant #01	—	R 31 658	21d	5.5 mo	—	4	R 126 634 PFS proxy	1
EP-Topotecan Variant #01	—	R 19 811	21d	—	10.2 mo	4	R 79 242 PFS proxy	—
VIP Variant #01	—	R 13 835	21d	—	—	~4	~R 55 342 indirect	—
ICE-V Variant #01	—	R 13 514	28d	—	15.6 mo	6	R 81 085 PFS proxy	1
ICE Variant #05	—	R 12 735	—	—	13.9 mo	4	R 50 942 PFS proxy	—
IVE Variant #01	—	R 12 663	21d	—	10.0 mo	2	R 25 326 PFS proxy	1
EVI Variant #01 Partial	—	R 12 200	21d	—	—	~6	~R 73 200 indirect	—
Ifosfamide monotherapy Variant #05	—	R 8 704	21d	~4.0 mo	~8.4 mo	~8	~R 69 635 PFS proxy · indirect	2
CEV (Carboplatin/Etoposide) Variant #01	—	R 4 376	—	—	—	~3	~R 13 127 indirect	—
PCE Variant #01	—	R 3 876	21d	—	—	~9	~R 34 882 indirect	—
VMV-VAC Variant #01	—	R 3 522	21d	—	—	~4	~R 8 023 indirect	—
PCDE Variant #01	—	R 3 144	28d	—	8.7 mo	6	R 18 864 PFS proxy	1
CDE Variant #04	—	R 2 958	21d	4.9 mo	12.4 mo	6	R 17 749 PFS proxy	—
Docetaxel monotherapy Variant #02	—	R 2 921	28d	~3.2 mo	~9.8 mo	~8	~R 23 372 PFS proxy · indirect	52
Carboplatin and Etoposide (CE) and Tislelizumab Variant #01 Partial	—	R 2 569	21d	—	15.5 mo	5	R 10 275 PFS proxy	1
Carboplatin and Etoposide (CE) and Serplulimab Variant #01 Partial	—	R 2 569	21d	—	15.6 mo	5	R 10 275 PFS proxy	2
CEV (Cyclophosphamide/Etoposide) Variant #01	—	R 2 424	21d	—	—	~2	~R 4 847 indirect	—
Carboplatin and Etoposide (CE) Variant #01	—	R 2 301	28d	4.4 mo	10.6 mo	7	R 16 108 PFS proxy	16
Carboplatin and Irinotecan Variant #01	—	R 2 277	21d	—	8.5 mo	4	R 9 109 PFS proxy	1
CAVE Variant #01	—	R 2 196	21d	—	—	~6	~R 13 178 indirect	—
Cisplatin and Etoposide (EP) Variant #22	—	R 1 819	21d	5.0 mo	10.2 mo	6	R 10 916 PFS proxy	10
Cisplatin and Irinotecan (IC) Variant #01	—	R 1 795	21d	—	10.2 mo	4	R 7 181 PFS proxy	3
Cisplatin and Etoposide (EP) and Tislelizumab Variant #01 Partial	—	R 1 672	21d	—	15.5 mo	5	R 6 689 PFS proxy	1
CEV (Cyclophosphamide/Epirubicin) Variant #01	—	R 1 566	21d	—	—	~5	~R 7 829 indirect	—
CAV/PE Variant #02	—	R 1 478	21d	—	—	~3	~R 4 435 indirect	—
Cyclophosphamide, Lomustine, Methotrexate Variant #01 Partial	—	R 1 176	42d	—	—	~1	~R 1 176 indirect	—
CAV Variant #06	—	R 865	21d	—	~7.6 mo	~6	~R 5 188 PFS proxy · indirect	1
BACO Variant #01 Partial	—	R 858	21d	—	—	~9	~R 7 725 indirect	—
Belotecan and Cisplatin Variant #01 Partial	—	R 441	21d	—	—	~8	~R 3 530 indirect	—
Cyclophosphamide, Lomustine, Procarbazine Variant #01 Partial	—	R 351	42d	—	—	~2	~R 702 indirect	—
Cyclophosphamide and Lomustine Variant #01 Partial	—	R 351	42d	—	—	~2	~R 702 indirect	—
Teniposide monotherapy Variant #01 Partial	—	—	21d	—	—	~12	—	—

39 of 39 regimens shown